Compare · INDV vs NVO
INDV vs NVO
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 40.9x INDV ($4.69B).
- Over the past year, INDV is up 180.0% and NVO is down 43.1% - INDV leads by 223.1 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 1 for INDV).
- NVO has more recent analyst coverage (25 ratings vs 6 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $37.60+0.43%
- $42.94-1.84%
- Market cap
- $4.69B
- $191.82B
- 1M return
- -7.42%
- -6.14%
- 1Y return
- +179.97%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INDV
- New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)
- Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)
- Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)
- Director Ninivaggi Daniel A was granted 6,518 shares, increasing direct ownership by 32% to 27,163 units (SEC Form 4)
- Director Ryan Barbara was granted 6,518 shares, increasing direct ownership by 114% to 12,242 units (SEC Form 4)
- Director Stejbach Mark was granted 6,518 shares, increasing direct ownership by 32% to 27,087 units (SEC Form 4)
- Director Wheadon David E. was granted 10,430 shares, increasing direct ownership by 51% to 30,780 units (SEC Form 4)
- Indivior to Participate in Upcoming Investor Conferences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates